173 related articles for article (PubMed ID: 29355613)
21. Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment.
Zaharia C; Veen T; Lea D; Kanani A; Alexeeva M; Søreide K
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612177
[TBL] [Abstract][Full Text] [Related]
22. Morphological aspects of the hepatic response to neoadjuvant therapy.
Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
[TBL] [Abstract][Full Text] [Related]
23. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.
Passiglia F; Caglevic C; Giovannetti E; Pinto JA; Manca P; Taverna S; Listì A; Gil-Bazo I; Raez LE; Russo A; Rolfo C
Semin Cancer Biol; 2018 Oct; 52(Pt 2):259-268. PubMed ID: 29391205
[TBL] [Abstract][Full Text] [Related]
24. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
Li X; Nie J; Mei Q; Han WD
World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
[TBL] [Abstract][Full Text] [Related]
25. Role of mTOR Signaling in Tumor Microenvironment: An Overview.
Conciatori F; Bazzichetto C; Falcone I; Pilotto S; Bria E; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126252
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-inducible factors: a central link between inflammation and cancer.
Triner D; Shah YM
J Clin Invest; 2016 Oct; 126(10):3689-3698. PubMed ID: 27525434
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
[TBL] [Abstract][Full Text] [Related]
28. Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients.
Bohlok A; Vermeulen P; Leduc S; Latacz E; Botzenhart L; Richard F; De Schepper M; Geukens T; Lucidi V; Ignatiadis M; Aftimos P; Sotiriou C; Piccart M; Hendlisz A; Van Laere S; Dirix L; Noël JC; Biganzoli E; Larsimont D; Desmedt C; Donckier V
NPJ Breast Cancer; 2020 Dec; 6(1):64. PubMed ID: 33339824
[TBL] [Abstract][Full Text] [Related]
29. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
30. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
31. The paradox of Th17 cell functions in tumor immunity.
Asadzadeh Z; Mohammadi H; Safarzadeh E; Hemmatzadeh M; Mahdian-Shakib A; Jadidi-Niaragh F; Azizi G; Baradaran B
Cell Immunol; 2017 Dec; 322():15-25. PubMed ID: 29103586
[TBL] [Abstract][Full Text] [Related]
32. Neutrophils: important contributors to tumor progression and metastasis.
Swierczak A; Mouchemore KA; Hamilton JA; Anderson RL
Cancer Metastasis Rev; 2015 Dec; 34(4):735-51. PubMed ID: 26361774
[TBL] [Abstract][Full Text] [Related]
33. Chemokines in cancer.
Chow MT; Luster AD
Cancer Immunol Res; 2014 Dec; 2(12):1125-31. PubMed ID: 25480554
[TBL] [Abstract][Full Text] [Related]
34. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Van den Eynden GG; Van der Auwera I; Van Laere SJ; Colpaert CG; Turley H; Harris AL; van Dam P; Dirix LY; Vermeulen PB; Van Marck EA
Br J Cancer; 2005 Nov; 93(10):1128-36. PubMed ID: 16251878
[TBL] [Abstract][Full Text] [Related]
35. Focused Ultrasound for Immunomodulation of the Tumor Microenvironment.
Joiner JB; Pylayeva-Gupta Y; Dayton PA
J Immunol; 2020 Nov; 205(9):2327-2341. PubMed ID: 33077668
[TBL] [Abstract][Full Text] [Related]
36. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Sluiter NR; de Cuba EM; Kwakman R; Meijerink WJ; Delis-van Diemen PM; Coupé VM; Beliën JA; Meijer GA; de Hingh IH; te Velde EA
Clin Exp Metastasis; 2016 Apr; 33(4):297-307. PubMed ID: 26873137
[TBL] [Abstract][Full Text] [Related]
37. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.
Marien KM; Croons V; Martinet W; De Loof H; Ung C; Waelput W; Scherer SJ; Kockx MM; De Meyer GR
Expert Rev Mol Diagn; 2015 Mar; 15(3):399-414. PubMed ID: 25585649
[TBL] [Abstract][Full Text] [Related]
38. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
40. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
Burugu S; Asleh-Aburaya K; Nielsen TO
Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
